Abstract
Background and Objective: Asenapine is an atypical antipsychotic approved by US Food and Drug Administration in 2009 and by European Medicines Agency in 2010 for Schizophrenia and Bipolar Disorder treatment. Currently, many studies have been developed in an attempt to clarify and minimize the risks related to the use of psychotropic during pre/postnatal period on patients with a history of mental disorders.
Conclusion: The aim of this study was to test the impact of pre and/or postnatal exposition to asenapine on mice offspring behavior. Four groups of animals, previously treated with a dosage equivalent to 50% of the bioavailability obtained with a 20 mg daily use for human treatment, were exposed to the Open Field and Elevated plus Maze test. Only the group exposed to asenapine during both pre and postnatal periods showed response difference in the Elevated Plus Maze test, which was restricted to urination. However, our data suggest that the administration of asenapine does not induce significant anxiety-like behaviors in mice.
Keywords: Antipsychotic, schizophrenia, bipolar disorder, behaviour, anxiety, stress, open field, elevated plus maze.
CNS & Neurological Disorders - Drug Targets
Title:Systemic Administration of Antipsychotic Asenapine Pre or Postnatal does not Induce Anxiety-like Behaviors in Mice
Volume: 16 Issue: 10
Author(s): Thais Barbosa de Souza, Daniela Miranda Farias, Rozimeri Fatima Coletti, Maria Silvia Oliveira, Carolina Gomes Carrilho, Jorge Aparecido de Barros, Susana Elisa Moreno, Eric Murillo-Rodriguez, Sergio Machado and Andre Barciela Veras*
Affiliation:
- Intercontinental Neuroscience Research Group, Campo Grande,Brazil
Keywords: Antipsychotic, schizophrenia, bipolar disorder, behaviour, anxiety, stress, open field, elevated plus maze.
Abstract: Background and Objective: Asenapine is an atypical antipsychotic approved by US Food and Drug Administration in 2009 and by European Medicines Agency in 2010 for Schizophrenia and Bipolar Disorder treatment. Currently, many studies have been developed in an attempt to clarify and minimize the risks related to the use of psychotropic during pre/postnatal period on patients with a history of mental disorders.
Conclusion: The aim of this study was to test the impact of pre and/or postnatal exposition to asenapine on mice offspring behavior. Four groups of animals, previously treated with a dosage equivalent to 50% of the bioavailability obtained with a 20 mg daily use for human treatment, were exposed to the Open Field and Elevated plus Maze test. Only the group exposed to asenapine during both pre and postnatal periods showed response difference in the Elevated Plus Maze test, which was restricted to urination. However, our data suggest that the administration of asenapine does not induce significant anxiety-like behaviors in mice.
Export Options
About this article
Cite this article as:
de Souza Barbosa Thais , Farias Miranda Daniela , Coletti Fatima Rozimeri , Oliveira Silvia Maria , Carrilho Gomes Carolina, de Barros Aparecido Jorge , Moreno Elisa Susana, Murillo-Rodriguez Eric , Machado Sergio and Veras Barciela Andre *, Systemic Administration of Antipsychotic Asenapine Pre or Postnatal does not Induce Anxiety-like Behaviors in Mice, CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/1871527317666171213162403
DOI https://dx.doi.org/10.2174/1871527317666171213162403 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Early Life and Oxidative Stress in Psychiatric Disorders: What Can we Learn From Animal Models?
Current Pharmaceutical Design Mitochondrial Neuroprotection in Traumatic Brain Injury: Rationale and Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
Current Drug Targets Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Multi-Target Drug Discovery in Medicinal Chemistry: Current Status and Future Perspectives)
Mini-Reviews in Medicinal Chemistry Glutamate-Mediated Signaling and Autism Spectrum Disorders: Emerging Treatment Targets
Current Pharmaceutical Design 1950 MHz Electromagnetic Fields Ameliorate Aβ Pathology in Alzheimer’s Disease Mice
Current Alzheimer Research New Targets for Treating the Underlying Pathophysiology and Nonmotor Aspects of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Current View from Alzheimer Disease to Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets AMPA Glutamate Receptors and Neuropathic Pain
Mini-Reviews in Medicinal Chemistry The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
CNS & Neurological Disorders - Drug Targets Regulatory T Cells in Central Nervous System: in Health and Disease
Central Nervous System Agents in Medicinal Chemistry